Recent positive Phase 3 results for the Merck-Moderna personalized mRNA cancer vaccine in melanoma, announced August 19, 2026, have reinforced their established collaboration and boosted both stocks sharply without signaling any shift toward full acquisition. Merck continues executing smaller deals, including Terns and Cidara, to diversify beyond the impending Keytruda patent cliff while maintaining its preference for targeted BD rather than large transformative M&A. Absent regulatory filings, activist pressure, or strategic commentary indicating merger talks, trader consensus prices the 2026 probability of an announced deal at just 14% for Yes. Upcoming catalysts such as further trial readouts or earnings commentary are unlikely to alter this assessment absent new developments.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoSí
26% probabilidad
NUEVO
NUEVO
31 dic 2026
Sí
26% probabilidad
NUEVO
NUEVO
31 dic 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results for the Merck-Moderna personalized mRNA cancer vaccine in melanoma, announced August 19, 2026, have reinforced their established collaboration and boosted both stocks sharply without signaling any shift toward full acquisition. Merck continues executing smaller deals, including Terns and Cidara, to diversify beyond the impending Keytruda patent cliff while maintaining its preference for targeted BD rather than large transformative M&A. Absent regulatory filings, activist pressure, or strategic commentary indicating merger talks, trader consensus prices the 2026 probability of an announced deal at just 14% for Yes. Upcoming catalysts such as further trial readouts or earnings commentary are unlikely to alter this assessment absent new developments.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Mercado abierto: Aug 19, 2026, 3:58 PM ET
Volumen
$0Fecha de finalización
31 dic 2026Mercado abierto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results for the Merck-Moderna personalized mRNA cancer vaccine in melanoma, announced August 19, 2026, have reinforced their established collaboration and boosted both stocks sharply without signaling any shift toward full acquisition. Merck continues executing smaller deals, including Terns and Cidara, to diversify beyond the impending Keytruda patent cliff while maintaining its preference for targeted BD rather than large transformative M&A. Absent regulatory filings, activist pressure, or strategic commentary indicating merger talks, trader consensus prices the 2026 probability of an announced deal at just 14% for Yes. Upcoming catalysts such as further trial readouts or earnings commentary are unlikely to alter this assessment absent new developments.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volumen
$0Fecha de finalización
31 dic 2026Mercado abierto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Recent positive Phase 3 results for the Merck-Moderna personalized mRNA cancer vaccine in melanoma, announced August 19, 2026, have reinforced their established collaboration and boosted both stocks sharply without signaling any shift toward full acquisition. Merck continues executing smaller deals, including Terns and Cidara, to diversify beyond the impending Keytruda patent cliff while maintaining its preference for targeted BD rather than large transformative M&A. Absent regulatory filings, activist pressure, or strategic commentary indicating merger talks, trader consensus prices the 2026 probability of an announced deal at just 14% for Yes. Upcoming catalysts such as further trial readouts or earnings commentary are unlikely to alter this assessment absent new developments.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes